These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24439762)

  • 1. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis.
    Stanisławowski M; Wiśniewski P; Guzek M; Wierzbicki PM; Adrych K; Smoczyński M; Sworczak K; Celiński K; Kmieć Z
    J Crohns Colitis; 2014 Aug; 8(8):802-10. PubMed ID: 24439762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases.
    Krela-Kaźmierczak I; Szymczak-Tomczak A; Łykowska-Szuber L; Wysocka E; Michalak M; Stawczyk-Eder K; Waszak K; Linke K; Eder P
    Adv Clin Exp Med; 2018 Apr; 27(4):449-453. PubMed ID: 29558031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
    Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
    Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
    Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing.
    Kon T; Cho TJ; Aizawa T; Yamazaki M; Nooh N; Graves D; Gerstenfeld LC; Einhorn TA
    J Bone Miner Res; 2001 Jun; 16(6):1004-14. PubMed ID: 11393777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
    Shaarawy M; Fathy SA; Mehany NL; Hindy OW
    Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/RANK/OPG system and bone status in females with anorexia nervosa.
    Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Szapska B; Wołkowska-Pokrywa K; Dyduch A
    Bone; 2012 Jan; 50(1):156-60. PubMed ID: 22001124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women.
    Ostrowska Z; Kos-Kudła B; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K
    Postepy Hig Med Dosw (Online); 2011 Oct; 65():658-67. PubMed ID: 22100799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
    J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of zinc supplementation against cadmium-induced oxidative stress and the RANK/RANKL/OPG system imbalance in the bone tissue of rats.
    Brzóska MM; Rogalska J
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):208-20. PubMed ID: 23726800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption.
    Tunyogi-Csapo M; Kis-Toth K; Radacs M; Farkas B; Jacobs JJ; Finnegan A; Mikecz K; Glant TT
    Arthritis Rheum; 2008 Aug; 58(8):2397-408. PubMed ID: 18668542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis.
    Yu M; Su Y; Cui D; Sun Q; Luan B; Zhao D
    J Cancer Res Ther; 2016; 12(2):963-8. PubMed ID: 27461682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism.
    Baek KH; Oh KW; Lee WY; Tae HJ; Rhee EJ; Han JH; Cha BY; Kim YJ; Lee KW; Son HY; Kang SK; Kim CC; Kang MI
    Bone; 2006 Dec; 39(6):1352-60. PubMed ID: 16905375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
    Bernstein CN; Sargent M; Leslie WD
    Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
    Szymczak J; Bohdanowicz-Pawlak A
    Horm Metab Res; 2013 Sep; 45(10):759-64. PubMed ID: 23888411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of low-level laser on the expression of interleukin-6, tumor necrosis factor‑α, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in human periodontal ligament cells.
    Tang M; Cui ZQ; Wang Y; Chen Z; Li W; Zhang C
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2023 Oct; 41(5):521-532. PubMed ID: 37805676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
    Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
    Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.